Resection of liver metastases from breast cancer: a multicentre analysis

• X. He ^[5] ; Q. Zhang ^[1] ; Y. Feng ^[5] ; Z. Li ^[2] ; Q. Pan ^[5] ; Y. Zhao ^[5] ; W. Zhu ^[5] ; N. Zhang ^[5] ; J. Zhou ^[5] ; L. Wang ^[5] ; M. Wang ^[5] ; Z. Liu ^[3] ; H. Zhu ^[5] ; Z. Shao ^[4] ; L. Wang ^[5]
  1. [1] Zhongshan Hospital

     Zhongshan Hospital

     China

     
  2. [2] Second Military Medical University

     Second Military Medical University

     China

     
  3. [3] Qilu Hospital of Shandong University

     Qilu Hospital of Shandong University

     China

     
  4. [4] Fudan University

     Fudan University

     China

     
  5. [5] Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, China

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 4, 2020, págs. 512-521
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Surgery is becoming more practical and effective than conservative treatment in improving the poor outcomes of patients with breast cancer liver metastasis (BCLM). However, there is no generally acknowledged set of standards for identifying BCLM candidates who will benefit from surgery.

    Methods Between January 2011 and September 2018, 67 female BCLM patients who underwent partial hepatectomy were selected for analysis in the present study. Prognostic factors after hepatectomy were determined. Univariate and multivariate analyses were performed to identify predictors of overall survival (OS) and intrahepatic recurrence-free survival (IHRFS).

    Results The 1-, 3- and 5-year OS of patients treated with surgery was 93.5%, 73.7% and 32.2%, respectively, with a median survival time of 57.59 months. The Pringle manoeuvre [hazard radio (HR) = 0.117, 95% CI0.015–0.942, p = 0.044] and an increased interval between breast surgery and BCLM diagnosis (HR0.178, 95% CI 0.037–0.869, p = 0.033) independently predicted improved overall survival for BCLM patients. The 1-, 2- and 3-year IHRFS of patients who underwent surgery was 62.8, 32.6% and 10.9%, respectively, with a median intrahepatic recurrence-free survival time of 13.47 months. Moderately differentiated tumours (HR  0.259, 95% CI 0.078–0.857, p = 0.027) and the development of liver metastasis more than 2 years after breast surgery (HR  0.270, 95% CI 0.108–0.675, p = 0.005) might be predictors of increased IHRFS.

    Conclusions An interval of more than 2 years between breast cancer surgery and liver metastasis seems to be an indication of liver surgery in BCLM patients. The Pringle manoeuvre and moderately differentiated tumours are potential predictors associated with OS and IHRFS, respectively, as benefits from liver resection. Studies with increased sample sizes are warranted to validate our results.